Optometric Management magazine

01/27/2026

Time to Prepare to Offer In-Office Laser Care?
https://www.optometricmanagement.com/issues/2026/januaryfebruary/viewpoint-time-to-prepare-to-offer-in-office-laser-care/

-OfficeLaserProcedures

01/26/2026

Set your practice apart with the first and only FDA market authorized spectacle lens designed for myopia control in children*¹. This groundbreaking innovation (Essilor® Stellest® lenses) is a major milestone on our mission to empower people and allow them to greater control their health destiny.​
Learn more here: https://bit.ly/4be66Is


*Compared to single vision lenses. Results from a prospective, randomized, double-masked, multicenter U.S. clinical trial in myopic children aged 6–12 years at initiation of treatment.
1.Essilor International, data on file (2025)

01/26/2026

As an eye care professional, expand your myopia management toolkit with the only FDA market authorized spectacle lens for slowing myopia progression in children*¹. Seamless to prescribe, simple to dispense, proven to perform*¹.
Learn more here: https://bit.ly/469DzAe


*Compared to single vision lenses. Results from a prospective, randomized, double-masked, multicenter U.S. clinical trial in myopic children aged 6–12 years at initiation of treatment.
1.Essilor International, data on file (2025)

Stellest® lenses are Essilor®’s latest innovation to slow down myopia progression in children. Essilor® Stellest® lenses slow down myopia progression by 67% on average, compared to single vision lenses, when worn 12 hours a day3

01/26/2026

Essilor® Stellest® Lenses slowed axial elongation by 0.24 mm on average over 2 years*¹. Bring trusted, science-backed innovation into your practice — and meet growing parental demand with a non-invasive, everyday solution with FDA market authorization to slow myopia progression in children*¹.
Discover more here: https://bit.ly/4qvgfFn


*Compared to single vision lenses. Results from a prospective, randomized, double-masked, multicenter U.S. clinical trial in myopic children aged 6–12 years at initiation of treatment.
1.Essilor International, data on file (2025)

Stellest® lenses are Essilor®’s latest innovation to slow down myopia progression in children. Essilor® Stellest® lenses slow down myopia progression by 67% on average, compared to single vision lenses, when worn 12 hours a day3

01/26/2026

Slow myopia progression in children,†1 with H.A.L.T.* technology: a constellation of invisible‡ lenslets. The lens design ensures a large prescription zone providing best corrected visual acuity and comfort. An easy to use and proven†1 way to help manage children's myopia.
Learn more here: https://bit.ly/3LOtySf


*H.A.L.T. is an acronym for Highly Aspherical Lenslet Target and does not imply a “halt” or “stop” of myopia progression.
†Compared to single vision lenses. Results from a prospective, randomized, double-masked, multicenter U.S. clinical trial in myopic children aged 6–12 years at initiation of treatment.
‡Aesthetic finish
1.Essilor International, data on file (2025)

Stellest® lenses are Essilor®’s latest innovation to slow down myopia progression in children. Essilor® Stellest® lenses slow down myopia progression by 67% on average, compared to single vision lenses, when worn 12 hours a day3

01/26/2026

Our mission is to support every child’s vision. Essilor® Stellest® Lenses are clinically proven to slow myopia progression in children*¹. Set your practice apart with the first and only FDA market authorized spectacle lens designed for myopia control in children*¹. Learn more here:
Optometrists: https://bit.ly/4pS8yb0
Opticians: https://bit.ly/49BkQQv


*Compared to single vision lenses. Results from a prospective, randomized, double-masked, multicenter U.S. clinical trial in myopic children aged 6–12 years at initiation of treatment.
1.Essilor International, data on file (2025)

01/26/2026

When it comes to children’s myopia management, it’s important to look beyond correction alone. Essilor® Stellest® Lenses slowed myopia progression by 71% on average over 2 years*¹. Bring trusted, science-backed innovation into your practice by choosing Essilor® Stellest® Lenses.
Learn more here: https://bit.ly/49KUWbK


*Compared to single vision lenses. Results from a prospective, randomized, double-masked, multicenter U.S. clinical trial in myopic children aged 6–12 years at initiation of treatment.
1.Essilor International, data on file (2025)

01/23/2026

Alert! Discover Essilor® Stellest® lenses, the first and only FDA market authorized spectacle lens to slow myopia progression in children*¹. With a mission to support every child’s vision, Essilor® brings trusted, science-backed innovation to your practice. Tune in to the Optometric Management Facebook on Monday, Jan. 26 for more information about Essilor®
Stellest® lenses.
Learn more: https://bit.ly/3LOoVaP


*Compared to single vision lenses. Results from a prospective, randomized, double-masked, multicenter U.S. clinical trial in myopic children aged 6–12 years at initiation of treatment.
Reference: 1.Essilor International, data on file (2025)"

Stellest® lenses are Essilor®’s latest innovation to slow down myopia progression in children. Essilor® Stellest® lenses slow down myopia progression by 67% on average, compared to single vision lenses, when worn 12 hours a day3

01/23/2026

Primera Professional Pharmacy Introduces the Demovectin Kit
https://www.optometricmanagement.com/news/2026/primera-professional-pharmacy-introduces-the-demovectin-kit/

01/22/2026

Therapeutic Focus: Dropping Some Knowledge
https://www.optometricmanagement.com/issues/2026/januaryfebruary/therapeutic-focus-dropping-some-knowledge/

01/21/2026

Introducing Occupational Lenses for Presbyopia
https://www.optometricmanagement.com/issues/2026/januaryfebruary/presbyopia-introducing-occupational-lenses/

-variableFocusLenses

01/20/2026

Adding Aesthetics for Dry Eye
https://www.optometricmanagement.com/issues/2026/januaryfebruary/dry-eye-adding-aesthetics/

-SafeCosmetics